Effective B cell depletion with rituximab in the treatment of autoimmune diseases.
about
Regeneration of the immunoglobulin heavy-chain repertoire after transient B-cell depletion with an anti-CD20 antibody.Rituximab for chronic recurring thrombotic thrombocytopenic purpura: a case report and review of the literature.Mycophenolate mofetil as a treatment for refractory idiopathic thrombocytopenic purpura.Anti-CD20 therapy in patients with refractory systemic lupus erythematosus: a longitudinal analysis of 52 Hispanic patients.Immunologic effects of rituximab on the human spleen in immune thrombocytopenia.Anti B-cell therapy against refractory thrombocytopenia in SLE and MCTD patients: long-term follow-up and review of the literature.Hydroxychloroquine is a good second-line treatment for adults with immune thrombocytopenia and positive antinuclear antibodies.Efficacy and Safety of Rituximab in Systemic Lupus Erythematosus and Sjögren Syndrome Patients With Refractory Thrombocytopenia: A Retrospective Study of 21 Cases.Emerging Role of the Spleen in the Pharmacokinetics of Monoclonal Antibodies, Nanoparticles and Exosomes.An update on the use of biologic therapies in the management of uveitis in Behçet's disease: a comprehensive review.Relevance of rituximab therapy in pemphigus vulgaris: analysis of current data and the immunologic basis for its observed responses.Prolonged effects of short-term anti-CD20 B cell depletion therapy in murine systemic lupus erythematosus.B cells in autoimmune diabetesB lymphocytes in systemic lupus erythematosus: lessons from therapy targeting B cells.Diabetes tolerogenic vaccines targeting antigen-specific inflammationEmergence of targeted immune therapies for systemic lupus.B cells as a therapeutic target in autoimmune diseases.B-cell depletion with rituximab in the treatment of autoimmune diseases. Graves' ophthalmopathy the latest addition to an expanding family.New treatment strategies for proliferative lupus nephritis: keep children in mind!Biologic activity and safety of belimumab, a neutralizing anti-B-lymphocyte stimulator (BLyS) monoclonal antibody: a phase I trial in patients with systemic lupus erythematosusAssessment of rituximab's immunomodulatory synovial effects (ARISE trial). 1: clinical and synovial biomarker results.Rationale of anti-CD19 immunotherapy: an option to target autoreactive plasma cells in autoimmunity.B-cell subpopulations in humans and their differential susceptibility to depletion with anti-CD20 monoclonal antibodies.Targeting B cells in treatment of autoimmunity.CD19(+) CD20(-) CD27(hi) IL-s10-producing B cells are overrepresented in R-CHOP-treated DLBCL patients in complete remission.Treatment of myelitis in Behçet's disease with rituximab.Frequency of regulatory T cells is not affected by transient B cell depletion using anti-CD20 antibodies in rheumatoid arthritisCould we use a lower dose of rituximab to treat rheumatoid arthritis in clinical practice: pros and cons?Thrombocytopenia in lupus: baseline C3 as an independent risk factor for relapse.Rituximab in intractable ocular lesions of Behcet's disease; randomized single-blind control study (pilot study).Vaccine-induced tumor-specific immunity despite severe B-cell depletion in mantle cell lymphoma.
P2860
Q24817041-703E71C3-D153-493E-BBF6-70BAAC367347Q33359900-6511556A-5E02-4973-9730-9C2327FFAEEBQ33365907-285C5941-CB6B-4109-B50E-84B05C90EC5CQ33387348-07808B17-BE3D-4971-A926-3CA7BADBB085Q33396902-1EB77855-721B-49D2-A647-74462CF9BC9BQ33407247-E8D50F82-75A7-4DD8-9248-74BE6761EF8AQ33411608-7BCDAA91-D811-4D06-B810-86AA9E98336FQ33424691-EB47DC6D-8345-45CF-B60E-DD19D50EEA89Q33838871-EB818AF1-D2DD-4A8B-9065-6F99A5991450Q33910781-C53523BE-5C9C-424A-B1C0-79F5C8C13B45Q33971785-37AD76AC-E214-4C30-915A-5D2177E5FE63Q34063315-AE56E68C-E8CD-47D1-8B4B-2C6253F79E50Q35612697-AAB37C31-2AA6-44AB-81FA-299B0EAEE46FQ35824525-64A6B803-CD67-475E-BC16-1F4CD312D581Q35887037-253E65B1-E87C-4771-BA5F-F31EAD3CF49AQ36066014-1072F820-CC69-4B6D-A6D8-49883C79ACB3Q36158684-C61E42A6-5B2A-40A5-BA29-9ED3D3633A02Q36897408-D0A49EAB-7051-4817-88F5-5A34230FCDF1Q36915693-C721D3ED-6E2D-4B47-8166-599714E33C33Q36993242-1D1CE697-5CB7-4AAD-B798-5993CC568C39Q37367847-33B9A223-B784-44F7-B294-E10918002BF7Q38071110-B79A1218-5643-4CB3-8121-F913FE735C96Q38097170-122D5947-81E2-4B2C-8213-8D19106382C3Q38975656-65917EB4-40EB-4145-8A77-6F88B9B3D26DQ39720114-9D36573E-647C-49B6-85FA-94FA3CAEFF9BQ40114172-1EF181E3-F41C-4976-A3D0-D28ABF38DD74Q42096435-DEFE8D65-125D-42DE-95C5-CBEE7598A46EQ42745125-52E756ED-CD64-4360-A8CA-FA59FC033F18Q42774619-0D488C7E-CBA2-4CF8-B2A3-08CA7209FC00Q42939553-03F9AE51-DB8B-4F4F-BFE8-33191EC670A2Q51989383-40258A4E-6186-44C0-B770-12AA3EB8BED9
P2860
Effective B cell depletion with rituximab in the treatment of autoimmune diseases.
description
2002 nî lūn-bûn
@nan
2002 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Effective B cell depletion with rituximab in the treatment of autoimmune diseases.
@ast
Effective B cell depletion with rituximab in the treatment of autoimmune diseases.
@en
type
label
Effective B cell depletion with rituximab in the treatment of autoimmune diseases.
@ast
Effective B cell depletion with rituximab in the treatment of autoimmune diseases.
@en
prefLabel
Effective B cell depletion with rituximab in the treatment of autoimmune diseases.
@ast
Effective B cell depletion with rituximab in the treatment of autoimmune diseases.
@en
P356
P1433
P1476
Effective B cell depletion with rituximab in the treatment of autoimmune diseases.
@en
P2093
Christian Kneitz
Martin Wilhelm
P304
P356
10.1078/0171-2985-00200
P577
2002-12-01T00:00:00Z